Abstract
Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.
| Original language | English |
|---|---|
| Pages (from-to) | 168-171 |
| Number of pages | 4 |
| Journal | Blut |
| Volume | 41 |
| Issue number | 3 |
| Publication status | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin. / Bacigalupo, A.; Van Lint, M. T.; Cerri, R.
In: Blut, Vol. 41, No. 3, 1980, p. 168-171.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin
AU - Bacigalupo, A.
AU - Van Lint, M. T.
AU - Cerri, R.
PY - 1980
Y1 - 1980
N2 - Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.
AB - Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.
UR - http://www.scopus.com/inward/record.url?scp=0018934529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018934529&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0018934529
VL - 41
SP - 168
EP - 171
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 3
ER -